Compositions and methods for inhibiting expression of 17beta-hydroxysteroid dehydrogenase type 13 (hsd17b13)

EP4638742A1Pending Publication Date: 2025-10-29SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD

0 Cites 0 Cited by

Patent Information

Application Number: EP2023906071
Authority / Receiving Office: EP · EP
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2022-12-22
Filing Date: 2023-12-22
Publication Date: 2025-10-29

Application Information

Patent Timeline

22 Dec 2022

Priority

22 Dec 2023

Application

EP2023906071

29 Oct 2025

Publication

EP4638742A1

IPC: C12N15/11; C12N15/113; A61K31/713; A61P3/06

CPC: A61K31/713; A61P3/06; C12N15/1137; C12N2310/14; C12Y101/00; C12N2310/351; C12N2330/30; C12N2320/11

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Metabolism disorder

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Compositions and methods useful to reduce expression of 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) gene and for treatment of HSD 17B13-associated diseases and conditions are provided. Provided are HSD17B13 dsRNA agents, HSD17B13 antisense polynucleotide agents, compositions comprising HSD17B13 dsRNA agents, and compositions comprising HSD17B13 antisense polynucleotide agents that can be used to reduce HSD17B13 expression in cells and subjects.

Need to check novelty before this filing date? Find Prior Art